Visão geral do mercado global de injetáveis ​​por deficiência de ferro e previsão para 2031 – Análise de mercado e quota de mercado

Mercado global de injetáveis ​​por deficiência de ferro – Visão geral da indústria

A deficiência de ferro surge quando o organismo não tem ferro suficiente para produzir hemoglobina, levando à anemia por deficiência de ferro. Os sintomas incluem fadiga, fraqueza, pele pálida, falta de ar e tonturas. O mercado global de injetáveis ​​por deficiência de ferro está a registar um crescimento significativo impulsionado pelo aumento dos casos de anemia em todo o mundo, especialmente em regiões com acesso limitado a suplementos orais de ferro. Segundo a Organização Mundial de Saúde (OMS), a anemia afeta 1,62 mil milhões de pessoas, correspondendo a 24,8% da população. Alimentando em todo o mundo a procura por opções de tratamento rápidas e eficazes, como o ferro injetável.

O relatório de mercado de pesquisa de mercado da Data Bridge fornece detalhes dos novos desenvolvimentos recentes, quota de mercado, tendências de mercado com base nas suas segmentações e análises regionais, o impacto dos participantes do mercado, análises de oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações de mercado, estratégias análise de crescimento de mercado, tamanho de mercado, crescimento de mercado de categoria, nichos de aplicação e domínio, aprovações de produtos, lançamentos de produtos, expansões geográficas, inovações tecnológicas no mercado. Para mais informações sobre o mercado, contacte a equipa de analistas especializados da Data Bridge Market Research. A nossa equipa irá ajudá-lo a tomar decisões de mercado informadas para alcançar o crescimento do negócio.

Tamanho do mercado global de injetáveis ​​por deficiência de ferro

Com os avanços nas formulações de ferro injetável, como a carboximaltose férrica e o isomaltosídeo de ferro, o Injetável para Deficiência de Ferro está a sofrer uma maior aceitação devido aos perfis de segurança melhorados, à maior biodisponibilidade e à simplicidade de administração. Estas variáveis, juntamente com o aumento dos gastos em saúde e a maior consciencialização sobre as consequências da anemia para a saúde, provavelmente impulsionarão o crescimento global do mercado injetável por deficiência de ferro. Como resultado, a Databridge Market Research mergulhou na análise abrangente do mercado e revelou que o Mercado Global de Injetáveis ​​por Deficiência de Ferro está a aumentar a um CAGR de 9,20%. A nossa análise detalhada prevê que o mercado esteja avaliado em 12,14 mil milhões de dólares em 2023 e deverá crescer até 24,55 mil milhões de dólares até 2031. O nosso relatório meticulosamente criado, desenvolvido através de pesquisas e análises abrangentes, é um artigo distinto que revela dados reveladores sobre o mercado.

Dinâmica global do mercado de injetáveis ​​por deficiência de ferro

Global Iron Deficiency Injectable Market Growth Drivers

Prevalence of PCOS

According to the World Health Organization (WHO), PCOS affects an estimated 8–13% of women of reproductive age, translating to between 5% and 10% of women aged 15 to 44. Women with PCOS are more likely to develop iron deficiency anemia due to irregular menstrual cycles, which can cause excessive blood loss and chronic iron depletion. The growing awareness and diagnosis of PCOS, along with the rising prevalence of iron deficiency among affected women, contribute to the global iron deficiency injectable market growth.

Increasing prevalence of anemia

The increasing prevalence of anemia is a key growth factor for the worldwide iron deficiency injectable market. With anemia impacting 1.62 billion people, or 24.8% of the global population, there is an increasing demand for efficient and effective treatment alternatives. Injectable iron therapy have emerged as an important respond to, especially in areas where oral iron supplements are either unavailable, poorly tolerated, or inefficient. As awareness of anemia's widespread impact rises, healthcare practitioners are increasingly turning to injectable iron as a quick, dependable, and scalable therapy option, considerably contributing to Global Iron Deficiency Injectable market growth.

Global Iron Deficiency Injectable Market Growth Opportunities

Advancements in Injectable Iron Formulations

The introduction of newer formulations, such as ferric carboxymaltose and iron isomaltoside, have transformed treatment by providing superior safety and efficacy profiles compared to traditional oral supplements. For instance, ferric carboxymaltose enables for the administration of greater single doses of iron, up to 1,000 mg, in just 15 minutes, making it useful for patients with acute iron shortage who require immediate replenishment. Such formulations have improved patient outcomes and lowered side effects thus contributing to the Global Iron Deficiency Injectable Market growth.

Growing Pediatric and Geriatric Care Markets

Injectable iron is crucial for managing severe anemia in children who cannot benefit from oral supplements, especially in high-malnutrition regions, with tailored formulations enhancing treatment efficacy. Similarly, it offers a vital solution for elderly patients with absorption issues due to chronic conditions, improving management and quality of life. By addressing the unique needs of diverse age groups, the Global Iron Deficiency Injectable market can expand and provide effective solutions across diverse populations.

Global Iron Deficiency Injectable Market Growth Challenges

Risk of Adverse Reactions

Allergic reactions, including mild symptoms like rashes and itching to severe responses such as anaphylaxis, affect patients receiving intravenous iron. Local injection site reactions, such as discomfort, swelling, and redness, might impair patient comfort and adherence, limiting therapy acceptability. Additionally, long-term safety concerns concerning repeated injectable iron treatments include potential effects on organ systems, such as the liver, which necessitate continual monitoring to avoid iron overload and accompanying consequences. Consequently, posing a challenge for Global Iron Deficiency Injectable Market growth.

Lack of Patient Awareness

Patients often lack knowledge about the advantages of injectable iron over oral supplements, such as more rapid and effective treatment for severe anemia. For instance, injectable formulations like ferric carboxymaltose can deliver up to 1,000 mg of iron in a single dose, which is crucial for managing severe anemia where oral supplements may require extended periods to be effective. This lack of specific knowledge can lead to underutilization of injectable iron therapies, resulting in hindering Global Iron Deficiency Injectable Market growth.

Global Iron Deficiency Injectable Market Restraints

Regulatory and market approval hurdles

The complex regulatory landscapes across different regions can create significant barriers for the Global Iron Deficiency Injectable Market Growth. For instance, The Pharmaceuticals and Medical Devices Agency (PMDA) Regulations, Japan requires foreign companies to conduct additional clinical trials in Japan to verify the safety and efficacy of new injectable iron therapies within the Japanese population. These trials must adhere to Japanese Good Clinical Practice (GCP) guidelines. Such guidelines can significantly impact the timeline and cost for introducing new injectable iron therapies to these Iron Deficiency Injectable Market.

Global Iron Deficiency Injectable Market Scope and Trends

• Iron supplementation boosts RSL3-induced ferroptosis to both treat naïve prostate cancer and prevent castration-resistant prostate cancer.
• Ferric carboxymaltose (FCM), an injection utilized globally for treating iron deficiency in cancer and chronic kidney disease patients, has been shown by AIIMS doctors to be both effective and safe for pregnant women with moderate to severe anemia.
• Newer formulations, like iron isomaltoside 1000, have been shown to have fewer adverse reactions compared to older products, such as dextran-based irons, thereby broadening their use to more patients with varying health conditions.
• The Feraheme (ferumoxytol) auto-injector is designed to make at-home administration more accessible and less painful for patients.

Global Iron Deficiency Injectable Market Regional Analysis – Market Trends

Key Insights

• The U.S. and Canada are leading markets for iron deficiency injectables, driven by advanced healthcare systems and high iron deficiency rates. The U.S., in particular, sees significant use of products like ferric carboxymaltose and iron isomaltoside due to their effectiveness and convenience in treating severe anemia.
• Asia-Pacific region is experiencing rapid growth in the iron deficiency injectable market, with significant contributions from countries Such as China and India. Rising healthcare investments and increasing prevalence of iron deficiency anemia drive demand. In China, the use of injectable iron is expanding as part of the country’s broader efforts to address anemia, supported by government healthcare initiatives and growing awareness.
• European region benefits from well-established healthcare systems and regulatory frameworks that support the use of injectable iron therapies. In Germany, for instance, the availability of advanced injectable formulations aligns with the country’s high standards for patient care and treatment efficacy.

 Leading Players in the Global Iron Deficiency Injectable Market

• AbbVie Inc. (U.S.)
• Covis Pharma GmbH (U.S.)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• Fresenius Kabi AG (Germany)
• Vifor Pharma Management Ltd.(Switzerland)
• PHARMACOSMOS A/S (Denmark)
• Shield Therapeutics plc (U.K.)
• American Regent, Inc. (U.S.)
• Rockwell Medical, Inc. (U.S.)
• Apotex Inc (Canada)
• Bayer AG (Germany)
• Akebia Therapeutics, Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Aetna Inc.(U.S.)
• Pfizer Inc (U.S.)
• Systacare Remedies (India)
• BSA Pharma Inc. (India)

Global Iron Deficiency Injectable Market Recent Developments

• Em março de 2024 a Cadila Pharmaceuticals lança um injetável de ferro para tratar a anemia. A injeção de Redshot é uma preparação intravenosa de ferro com maior tolerabilidade e pouco ou nenhum risco de alergia.
• Em maio de 2023, a Emcure Pharmaceuticals, ao lançar o Orofer FCM 750, torna-se a primeira empresa indiana a lançar uma versão injetável de 750 mg de FCM para tratar a anemia por deficiência de ferro.
• Em maio de 2024, cientistas médicos indianos da AIIMS Delhi desenvolveram uma injeção intravenosa (IV) barata de ferro que não tem efeitos secundários, uma potencial ajuda à saúde num país com algumas das taxas de deficiência de ferro mais elevadas do mundo.
• Em junho de 2023, a FDA aprovou a injeção de carboximaltose férrica para o tratamento da deficiência de ferro em doentes adultos com insuficiência cardíaca classificada como classe 2 ou 3 da New York Heart Association (NYHA), com o objetivo de aumentar a capacidade de exercício .

SKU-57258